Introduction
Chronic phase (CP) chronic myelogenous leukemia (CML) is characterized by neutrophilic leukocytosis and it is effectively managed by the Bcr-Abl inhibitor imatinib (Ren, 2005) . Imatinib induces complete cytogenetic response in most newly diagnosed CP patients (Ren, 2005 ), yet it does not cure CML. Over time patients become resistant to treatment and progress toward blast crisis (BC; Ren, 2005) . BC patients respond less frequently to imatinib (Druker et al., 2001) due to the acquisition of additional genetic or epigenetic aberrations that drive the transition from CP to BC (Ren, 2005) . Several nonrandom chromosomal aberrations are associated with CP to BC transition (Barnes and Melo, 2002) . We recently investigated the role of the putative tumor suppressor Riz1 in CML (Pastural et al., 2007) , which is located at chromosome region 1p36 and undergoes loss of heterozygosity during the transformation from CP to BC (Mori et al., 1998) . Riz1 expression is reduced in BC (Takahashi et al., 2006) and in CML BC cell lines Riz1 represses insulin-like growth factor 1 (IGF-1) expression and autocrine signaling (Pastural et al., 2007) .
The importance of IGF-1 signaling in hematopoiesis (Akahane et al., 1987; Kurtz et al., 1988; Merchav et al., 1988a, b; Sanders et al., 1993; Zumkeller and Burdach, 1999) suggests that deregulation of IGF-1 expression may play a role in the CP to BC transition. IGF-1 is also important in leukemogenesis as seen by its ability to stimulate myeloid and lymphoid cells in culture (Johnson et al., 1992; Schwartz et al., 1996) , to stimulate proliferation of CML BC cell lines (Hizuka et al., 1987) , to increase bone marrow blast colony formation in patients with acute myeloid leukemia (AML; Zadik et al., 1993) and to promote growth of AML blasts (Doepfner et al., 2007) . IGF-1 mediated effects can be inhibited by IGF-1 receptor (IGF-1R) blocking antibodies (Merchav et al., 1988a; Doepfner et al., 2007; Pastural et al., 2007) and inhibitors AG1024 (Deutsch et al., 2004) and NVP-AEW541 (Doepfner et al., 2007; Tazzari et al., 2007) .
The role of IGF-1 signaling in leukemogenesis and the possible induction of autocrine IGF-1 signaling in BC highlights the therapeutic potential of this signaling pathway for treating BC. In this study, we aimed to elucidate signaling mechanisms used by CML BC cell lines to activate the IGF-1 expression. Previously, it has been shown that Bcr-Abl transforms a variety of cytokine-dependent cell lines to factor independence, possibly through its ability to induce expression of cytokines (Specchia et al., 1992; Zhang and Ren 1998; Jiang et al., 1999; Mayerhofer et al., 2002) . Based on these observations, we examined whether Bcr-Abl regulates IGF-1 expression and characterized downstream signaling components required to activate IGF-1 expression. We observed that IGF-1 expression is elevated in BC and found that Bcr-Abl activates IGF-1 expression in CML BC cell lines using hematopoietic cell kinase (Hck) and signal transducer and activator of transcription 5b (Stat5b). Inhibition of these pathway components using small molecule drugs or shRNA decreases proliferation and increases apoptosis. The effects of the Bcr-Abl inhibitor imatinib are partially reversed by the addition of exogenous IGF-1. Together, these results combined with studies showing the effect of IGF-1R inhibitors in treating CML, highlight the therapeutic potential of Bcr-Abl mediated autocrine IGF-1 signaling for treating CML BC.
Results

IGF-1 expression is increased in CML blast crisis
Previously, we showed that Riz1 represses IGF-1 expression in CML BC cell lines (Pastural et al., 2007) . To examine whether IGF-1 expression is enhanced in CML BC, we performed immunohistochemistry using an anti-IGF-1 antibody to measure IGF-1 expression in matched patient biopsies from CP and BC (Figure 1 ). We observed enhanced IGF-1 staining in BC of 8 of the 11 matched biopsies. Cases 9-11, which do not show increased IGF-1 expression in BC, have strong IGF-1 expression in CP.
Inhibition of Bcr-Abl tyrosine kinase activity decreases IGF-1 expression To determine if Bcr-Abl signaling is associated with IGF-1 activation, we assayed whether imatinib affects IGF-1 expression in CML BC cell lines. K562 cells were treated with 5 mM of imatinib and JURL-MK1 and KU-812 were treated 1 mM of imatinib, since these two cell lines have low viability at higher doses of imatinib. Treatment of all three CML BC cell lines with imatinib reduced IGF-1 mRNA (Figure 2a ) and protein expression (Figure 2b, Supplementary Figure 1 ) levels.
Stat5b regulates IGF-1 expression
Stat5b is a component of the growth hormone (GH) regulatory network that is responsible for IGF-1 expression (Herrington et al., 2000) . Stat5b knockout mice have reduced levels of IGF-1 (Teglund et al., 1998) and homozygous Stat5b mutations have been observed in a patient with reduced GH response and decreased IGF-1 serum levels (Kofoed et al., 2003) . Bcr-Abl constitutively activates Stat5b (Ilaria and Van Etten, 1996) and based on these observations, we assayed whether Stat5b is involved in Bcr-Abl mediated activation of IGF-1 expression. We investigated the role of Stat5b in regulating IGF-1 expression using Stat5b shRNA in K562 and JURL-MK1 cells. The viability of KU812 following transfection is too low to evaluate gene expression and cell phenotypes. To confirm that Bcr-Abl specifically activates Stat5b and not the closely related protein Stat5a, we immunoprecipitated Stat5a and Stat5b and assayed their phosphorylation state using an anti-phosphoTyr694-Stat5 antibody. When CML cell lines K562 and KU812 are treated with imatinib, we observe a decrease in phosphorylation in Stat5b only (Figure 2e ).
To determine whether Bcr-Abl-mediated activation of Stat5b increases Stat5b association with the IGF-1 promoter, we used chromatin immunoprecipitation (ChIP) assays with an anti-Stat5b antibody in K562 cells cultured in the presence and absence of imatinib. In humans and rats, distal 5 0 -flanking regions of the IGF-1 gene contain two consensus Stat5-binding sites, which mediate GH-induced IGF-1 gene activation (Wang and Jiang, 2005) . The DNAase hypersensitive region (HS-7) in the rat IGF-1 gene also contains two GH response elements with putative Stat5 binding sites that are conserved across mice and humans (Woelfle et al., 2003) . We observed that Stat5b associates with distal 5 0 -flanking and HS-7 regions of the IGF-1 gene and that imatinib decreases Stat5b binding to these regions (Figure 3f) .
We assayed the effects of Stat5b shRNA on viability, proliferation and apoptosis in CML BC cell lines. Stat5b shRNA has a stronger effect on viability, proliferation and apoptosis in K562 relative to JURL-MK1 (Supplementary Figure 3 ), which correlates with the levels of IGF-1 expression in K562 relative to JURL-MK1 (described below).
Together, these results demonstrate that Bcr-Abl tyrosine kinase activity is responsible for activating Stat5b, which increases Stat5b association with the distal 5 0 -flanking and HS-7 regions of the IGF-1 gene and enhances IGF-1 expression.
Hck regulates IGF-1 expression SH2 and SH3 domains of Bcr-Abl are required for constitutive Stat5b activation, however only very low amounts of Stat5b are associated with Bcr-Abl (Nieborowska-Skorska et al., 1999) . These results suggest that an intermediary tyrosine kinase is responsible for Stat5b activation. The GH receptor uses Janus kinase 2 (Jak2) as an intermediate tyrosine kinase to activate Stat5b (Herrington et al., 2000) . Bcr-Abl mediated activation of Stat5 however is independent of Jak2 (Ilaria and Van Etten, 1996) , which suggests that Stat5 activation occurs via a different mechanism. Recently, the Src kinase Hck has been identified as an intermediate for bridging Bcr-Abl activation of Stat5 (Klejman et al., 2002) .
To determine whether Jak2 or Hck participates in Bcr-Abl mediated activation of IGF-1, we monitored IGF-1 expression in the presence of the Jak2 inhibitor AG490 and the Src kinase inhibitor PP2. AG490 is a potent inhibitor of Jak2 with low activity against Src kinases (Meydan et al., 1996) . PP2 is a potent inhibitor of Src kinases with low Jak2 activity (Hanke et al., 1996) . Treatment of CML BC cell lines with AG490 did not alter IGF-1 mRNA (Figure 4a ) or protein (Figure 4b ) levels. AG490 inhibits viability and enhances apoptosis in KU812, but has no significant effect on K562 and JURL-MK1 (Supplementary Figure 4) . In contrast, PP2 treatment reduces IGF-1 mRNA Exogenous IGF-1 suppresses imatinib-induced effects on proliferation and apoptosis To determine whether CML BC cell lines respond to IGF-1, we examined whether exogenous IGF-1 reverses imatinib-induced decrease in proliferation and enhancement in apoptosis. Addition of exogenous IGF-1 to imatinib-treated cells enhances proliferation in K562 ( Figure 5a ) and decreases apoptosis in K562 and KU812 (Figures 5b and c). Exogenous IGF-1 however does not increase the number of imatinib-treated cells in G 2 /M phase of the cell cycle. We observed that imatinib reduces phosphorylation of Akt and Erk1/2 but only Akt phosphorylation is enhanced in imatinib-treated cells by the addition of IGF-1 (Figure 5d ). These results are consistent with the ability of IGF-1 to protect small cell lung cancer cell lines from imatinib-induced apoptosis by activating Akt (Krystal et al., 2000) . Together these results suggest that exogenous IGF-1 is primarily stimulating the pro-survival PI3K/Akt pathway in CML cell lines and that it cannot reactivate imatinib-repressed cell cycle progression genes.
Exogenous IGF-1 shows no significant effect on reversing imatinib-induced phenotypes in JURL-MK1. The ability of exogenous IGF-1 to reverse imatinibinduced phenotypes correlates with the higher IGF-1 expression levels in K562 and KU812 relative to JURL-MK1 (Figures 5e and f). Further, we observed almost no IGF-1 expression in megakaryocytes in our CML patient material, which suggests that the growth and survival of JURL-MK1, which has megakaryocytic features (Di Noto et al., 1997) , is independent of IGF-1.
Inhibition of IGF-1 receptor decreases proliferation and enhances apoptosis
We assayed the effect of blocking IGF-1R signaling using the IGF-1R inhibitor AG1024 (Parrizas et al., 1997) . Previously, we showed that an IGF-1R blocking antibody reduces the viability of CML BC cell lines (Pastural et al., 2007) . Similarly, AG1024 has been shown to inhibit clonogenic survival, proliferation and xenograft tumor growth, while enhancing apoptosis (Deutsch et al., 2004) . We analysed the effect of AG1024 on viability, proliferation and apoptosis in CML BC cell lines. We observed that AG1024 reduces viability (Figure 6a ), inhibits proliferation ( Figure 6b ) and enhances apoptosis (Figures 6c and d ) in K562 and KU812 and it has small effect on viability and proliferation in JURL-MK1. AG1024 activity correlates with IGF-1 expression in CML BC cell lines.
Discussion
IGF-1R signaling is necessary for progression through the cell cycle, growth and development . Increased IGF-1R and IGF-1 expressions are associated with a variety of cancers, where IGF-1R stimulates proliferation and motility and decreases apoptosis (Sachdev and Yee, 2007) . In several cancers, overexpression of IGF-1R and increased IGF-1R tyrosine kinase activity have been reported (Sachdev and Yee, 2007) and many of these cancers are inhibited by reagents that block IGF-1R activation (Baserga et al., ) and HS-7 using a Stat5b antibody in K562 cells treated overnight with 2.5 mM imatinib ( þ ) or PBS (À). ChIP PCR products were amplified from input positive controls, IgG negative controls and Stat5b antibody immunoprecipitates. Histograms show antibody/input ratios of PCR products quantified using real-time PCR. Asterisk (*) represents P-value o0.01 and double-asterisk (**) represents P-value o0.05 between imatinib treated and untreated cells. For panels a-d, cells were cultured for 48 h after transfection. For panels a, c and e, error bars represent s.d. from three independent measurements. . In addition to aberrant expression and activation, IGF-1R expression in fibroblasts is essential for transformation by some oncogenes (Valentinis and Baserga, 2001 ). Aberrant IGF-1R activation is also a mechanism for developing resistance to drugs that inactivate cytokine receptors. Switching to an activated IGF-1R has been reported as a mechanism for resistance against epidermal growth factor receptor inhibitors (Jones et al., 2006) . In normal hematopoiesis, IGFs are involved in erythropoiesis, granulopoiesis and lymphopoiesis (Shimon and Shpilberg, 1995) . Nearly all cell types express IGF-1R (Shimon and Shpilberg, 1995) and during differentiation IGF-1R expression is downregulated (Pepe et al., 1987) . IGF-1R is not activated by overexpression and needs ligand stimulation for activity (Kaleko et al., 1990) , which implies that IGF-1R activation requires endocrine, autocrine or paracrine IGF-1 production. The liver has traditionally been considered the main source for endocrine production of IGF-1, however IGF-1 is expressed in other tissues at various stages of development showing that IGF-1 can be produced locally in an autocrine or paracrine manner to affect differentiation and proliferation (LeRoith et al., 1991) . Expression of IGF-1 in normal hematopoietic cells suggests that hematopoiesis is regulated by IGF-1 autocrine or paracrine signaling (Majka et al., 2001) . Endogenously secreted IGF-1 has the potential to regulate adhesion, proliferation and apoptosis of hematopoietic cells and to regulate activity of accessory cells (Majka et al., 2001) . Therefore, it is not surprising that deregulation of endogenously secreted IGF-1 would contribute to altered IGF-1R signaling in CML.
There is growing evidence that autocrine loops contribute to malignant hematopoiesis in CML. BcrAbl transforms a variety of cytokine-dependent cell lines to factor independence, possibly through its ability to induce expression of cytokines such as IL-3, G-CSF, Autocrine IGF-1 signaling in CML A Lakshmikuttyamma et al GM-CSF, M-CSF, IL-1b and VEGF (Specchia et al., 1992; Zhang and Ren 1998; Jiang et al., 1999; Mayerhofer et al., 2002) . Induction of IGF-1 autocrine signaling may facilitate the transition from CP to BC, whereby CML cells in CP depend on the host for IGF-1 and in BC they produce IGF-1 in an autocrine manner, an event that might be responsible for the more aggressive behavior of BC cells. IGF-1R and Bcr-Abl signaling are typically regarded as separate entities that promote growth through the use of overlapping downstream signaling molecules. Our results show that Bcr-Abl regulates IGF-1 expression and that inhibition of IGF-1R reduces viability, proliferation and apoptosis in Bcr-Abl þ cells, which demonstrates crosstalk between IGF-1R and Bcr-Abl signaling. The ability of Bcr-Abl to regulate IGF-1 expression and the overlap in signaling molecules activated by Bcr-Abl and IGF-1R (Ren, 2005; Danielpour and Song, 2006) raises the question as to whether Bcr-Abl, IGF-1R or both molecules are responsible for aberrant activation of signaling pathways in BC. It is possible that Bcr-Abl and IGF-1R preferentially activate unique signaling pathways. Alternatively, they may both activate the same pathways and in BC, IGF-1R potentiates the activity of Bcr-Abl. Either way, in CP, Bcr-Abl enhances proliferation and viability of myeloid lineage cells but it does not result in BC phenotypes such as blockage of differentiation and acquisition of self-renewal. IGF-1R activation may be required for the Bcr-Abl induced BC phenotypes, which would be similar to the inability of several oncogenes to transform fibroblast in the absence of IGF-1R signaling (Sell et al., 1993; Coppola et al., 1994; Steller et al., 1996) . This hypothesis is supported by our results showing the ability of the IGF-1R inhibitor AG1024 to inhibit viability and enhance apoptosis in CML BC cell lines. The role of IGF-1 signaling in blocking differentiation and acquiring self-renewal capacity in BC is not clearly established. In murine hematopoietic 32D cells, IGF-1R activation enhances proliferation or differentiation depending of the expression levels of insulin receptor substrate 1 (IRS-1; Valentinis et al., 1999) . Further studies aimed at assessing the effect of IGF-1 and IRS-1 on differentiation in CML BC are needed to clarify this issue. Recently, it has been proposed that a CML BC stem cell with self-renewal capacity exists that has undergone partial differentiation toward a granulocytemacrophage progenitor (Jamieson et al., 2004) . Selfrenewal capacity is believed to result from enhanced b-catenin stability (Jamieson et al., 2004) . Bcr-Abl can phosphorylate b-catenin, which inhibits its association with Axin/GSK-3b complex and reduces its phosphorylation by GSK-3b and subsequent proteosomal degradation (Coluccia et al., 2007) . IGF-1R activation also Autocrine IGF-1 signaling in CML A Lakshmikuttyamma et al leads to b-catenin phosphorylation, stabilization and nuclear localization (Playford et al., 2000; Chen et al., 2005) . Thus, IGF-1 signaling may be responsible for b-catenin stability or it may cooperate with Bcr-Abl to further enhance b-catenin stability. Additional support for the role of IGF-1 signaling in self-renewal comes from the ability of exogenous IGF-1 to increase the clonogenic capacity in AML CD34 þ cells expressing IGF-1R (Tazzari et al., 2007) .
Our study reveals Bcr-Abl/Hck/Stat5b as a key pathway for regulating IGF-1 expression in CML BC cell lines. We demonstrate the therapeutic potential of Hck for inhibiting IGF-1 expression and for treating CML. Hck is the most likely Src kinase to mediate BcrAbl activation of IGF-1 expression in myeloid BC for the following reasons: (1) Myeloid cells express Hck and Lyn (Corey and Anderson, 1999) ; (2) Bcr-Abl activates Hck in 32D myeloid cells (Danhauser-Riedl et al., 1996) ; (3) Imatinib inhibits phosphorylation of Hck in CML BC cell lines (this work); (4) Hck and Lyn activate Stat5 (Schindler and Darnell, 1995; Klejman et al., 2002) ; (5) Stat5 is observed in immunoprecipitates with Hck but not Lyn (Klejman et al., 2002) ; (6) Purified Hck (Klejman et al., 2002) , and not Lyn (Gouilleux et al., 1994) , activates Stat5; (7) Kinase-defective Hck suppresses Bcr-Abl transforming signals in the cytokine-dependent myeloid leukemia cell line DAGM (Lionberger et al., 2000) ; (8) Hck shRNA inhibits IGF-1 expression (this work). Jak2 can also activate Stat5 (Schindler and Darnell, 1995) , however Jak2 is not consistently activated in Bcr-Abl-transformed cells (Ilaria and Van Etten, 1996) . Our results are similar to these observations as we show that the Jak2 inhibitor AG490 does not repress IGF-1 expression. Together these results suggest a model whereby Hck outcompetes Lyn and Jak2 for binding to Bcr-Abl. The therapeutic potential of using Hck inhibitors to treat CML has been demonstrated using Src kinase inhibitors. Src kinase inhibitors PP2 and A-419259 suppress CML BC cell-line proliferation and apoptosis, which correlates with decreased Src kinase autophosphorylation . PP2 also inhibits Bcr-Abl-dependent activation of Stat5b (Klejman et al., 2002; this work) . Recently, dual specific Src-and Abl-kinase inhibitors have shown significant activity in treating CML (Zhang and Meier, 2006) . Dasatinib, a multi-targeted inhibitor of Bcr-Abl and Src kinases, shows activity in imatinib resistant or intolerant CML in accelerated phase (Guilhot et al., 2007) . Dasatinib inhibits tyrosine phosphorylation of Src kinases Src, Hck and Lyn and decreases Stat5 phosphorylation in K562 cells (Nam et al., 2007) . The most compelling evidence for the role of Src kinases in CML is their involvement in the transformation of CP CML to lymphoid BC (Hu et al., 2006) . Src kinases remain active in imatinib-treated BcrAbl þ leukemic mice cells and they are essential for transformation to lymphoid BC, which suggests that imatinib does not inhibit all Bcr-Abl-signaling pathways (Hu et al., 2006) . This observation is consistent with the inability of imatinib to effectively treat BC (Druker et al., 2001) and to cure CML in mice (Hu et al., 2004) .
Together, these results suggest that other signaling components/pathways are important in BC and that targeting Hck should provide an effective therapeutic approach for blocking IGF-1 expression and inhibiting CML BC.
Stat5 has been identified as a potential therapeutic target for treating CML since it was first shown to be activated in Bcr-Abl-expressing cell lines and CML patient samples (Ilaria and Van Etten, 1996) . Stat5 dominant negative mutants block growth-factor independence and leukemogenic potential of Bcr-Abltransformed myeloid cells (Nieborowska-Skorska et al., 1999) . Stat5ab À/À mice die perinatally and liver hematopoietic progenitors from these mice transfected with Bcr-Abl fail to generate leukemia in recipient mice (Hoelbl et al., 2006) . RNAi-mediated reduction in Stat5 inhibits Bcr-Abl-dependent proliferation, but not cytokine-dependent proliferation and reduces myeloid colony formation in CML patient samples (Scherr et al., 2006) . The inability of Stat5 RNAi to inhibit cytokinedependent proliferation suggests that Stat5 is more important in mediating Bcr-Abl-specific signaling pathways. Similarly, our results show that reduction of Stat5b expression levels using Stat5b shRNA reduces CML BC cell-line viability and proliferation and enhances apoptosis. Further, our study identifies IGF-1 as a transcriptional target of Stat5b in BC and confirms that its association with the IGF-1 promoter is regulated by Bcr-Abl tyrosine kinase activity. Together, these results indicate that Stat5b is a good therapeutic target for treating CML. Currently, there are no available drugs for inhibiting Stat5b; however, a small molecule inhibitor has recently been developed against Stat3 (Siddiquee et al., 2007) , which suggests that Stat5b inhibitors can also be obtained.
IGF-1-signaling pathways have been implicated in the development and progression of many cancers (Pollak et al., 2004) . IGF-1R can be aberrantly activated by high levels of circulating IGF-1 or by autocrine production in neoplastic cells activation, which leads to deregulation of cell proliferation, anti-apoptosis, differentiation and cell motility (Pollak et al., 2004) . As described above, IGF-1 is required in many stages of hematopoiesis and deregulation of IGF-1R activation may be a driving event for the CP to BC transition. Recently it has been shown that IGF-1R inhibitors AG1024 (Deutsch et al., 2004) and NVP-AEW541 (Doepfner et al., 2007; Tazzari et al., 2007) have strong activity against CML and AML cells with autocrine IGF-1 secretion, respectively. We also observed that AG1024 inhibited viability, proliferation and enhanced apoptosis in CML BC cell lines with high IGF-1 expression (K562 and KU812) and showed weaker activity against our low IGF-1-expressing CML BC cell line (JURL-MK1).
In summary, our study highlights autocrine IGF-1 signaling as a potential mechanism for driving the transition from CP to BC. Further, we identified a BcrAbl-mediated signaling pathway involving Hck and Stat5b that regulates IGF-1 expression. These results suggest that acquisition of IGF-1 signaling is an important event in the transformation to BC and provide a novel mechanism to explain the activity of IGF-1R and Hck inhibitors in blocking BC phenotypes. Together, our results provide further support for the therapeutic potential of IGF-1-signaling components in treating CML, especially of CML cells with elevated autocrine IGF-1 expression. 
Materials and methods
Supplementary
Immunohistochemistry
Formalin fixed/paraffin embedded and decalcified bone marrow trephine biopsies and formalin fixed/paraffin embedded bone marrow aspirate clot samples were processed for immunostaining using an anti-IGF-1 antibody (1:100 dilution) using standard procedures.
Cell lines and culture CML blast crisis cell lines, K562, KU-812 and JURL-MK1 used in this study have the following characteristics (Drexler et al., 1999) : K562-erythrocytic cell type, triploid, multiple t(9;22) translocations, b3-a2 Bcr-Abl fusion; KU-812-myelocytic cell type, triploid, two t(9;22) translocations, b3-a2 Bcr-Abl fusion; JURL-MK1-erythro/megakaryocytic cell type, diploid, one t(9;22) translocations, b3-a2 Bcr-Abl fusion. K562 (CCL243) is obtained from ATCC (Manassas, VA, USA) and was cultured in IMDM media supplemented with 10% fetal calf serum (FCS), 100 IU ml À1 penicillin and 100 mg ml À1 streptomycin (Invitrogen, Burlington, Ontario, Canada). KU812 (ACC378) and JURL-MK1 (ACC532) are obtained from DSMZ (Braunschweig, Germany) and were cultured in RPMI supplemented with 100 IU ml À1 penicillin, 100 mg ml À1 streptomycin, and 20 and 10% FCS, respectively. For assays involving the addition of exogenous IGF-1 or AG1024, cells were cultured using the following conditions: K562 cells were starved in IMDM media supplemented with 100 IU ml À1 penicillin and 100 mg ml À1 streptomycin at 37 1C in 5% CO 2 for 16 h before the assay; KU812 cells were starved in RPMI supplemented with 5% FCS, 100 IU ml À1 penicillin and 100 mg ml À1 streptomycin; JURL-MK1 cells were starved in RPMI supplemented with 100 mg ml À1 streptomycin and 100 U ml À1 penicillin.
Transient transfection
Transient transfections were performed using the Nucleofector system (Amaxa Inc., Markham, Ontario, Canada) according to manufacturer's instructions using program T-016. Cells were starved 16-24 h post transfection and assays performed after 48 h.
Reverse transcription
Total RNA was isolated and cDNA synthesized as previously described (Pastural et al., 2007) . 
PCR
Immunoprecipitation
Immunoprecipitations were performed as previously described (Pastural et al., 2007) .
Chromatin immunoprecipitation
ChIP assays were performed using the ChIP assay kit from Upstate (Charlottesville, VA, USA). The distal IGF-1 promoter and the GH response element containing HS-7 (GenBank accession, AY79040) regions were amplified from the þ Ab, IgG and input. DNA samples were amplified and quantified using real-time PCR. Primer sequences for the ChIP assays are listed in Supplementary Table 1 .
Western analysis
Western analysis was performed as previously described (Pastural et al., 2007) .
Cell proliferation assay
Cell proliferation was measured using MTT assays as previously described (Pastural et al., 2007) .
Cell viability assay
Cell viability was determined using Trypan blue (Invitrogen) dye exclusion.
Apoptosis assay
Apoptotic cells were detected using the Annexin V-FITC Apoptosis Detection Kit (BD Biosciences Pharmingen, Franklin Lakes, NJ, USA) after 48 h of drug treatment or transfection.
Cell cycle analysis
Cell cycle analysis was performed as previously described (Scott et al., 2007) after 48 h of drug treatment or transfection.
Statistical analysis
All the data are reported as mean±s.d. The differences between the mean values were tested for statistical significance by the two-tailed Student's t-test (P-values).
